Inpharma Weekly

, Volume 1176, Issue 1, pp 13–14 | Cite as

Elucidating mechanisms of tamoxifen resistance in breast cancer

  • Robert Carlson
Newsletter Article


Estrogen receptor (ER)-positive breast tumours are stimulated by estrogen, and so antiestrogenic therapy has become a fundamental adjuvant therapy for many women with this disease. Tamoxifen is the gold standard for antiestrogen drugs, but residual tumour cells have a knack of developing resistance to tamoxifen, leading to disease recurrence. Overcoming tamoxifen resistance was a major topic at the 21st Annual San Antonio Breast Cancer Symposium [ San Antonio, US; December 1998 ]. Evidence was presented showing that the nature of tamoxifen itself may be the problem, as it has both estrogen-agonist and -antagonist properties.


Breast Cancer Tamoxifen Tamoxifen Therapy Tamoxifen Resistance Residual Tumour Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1999

Authors and Affiliations

  • Robert Carlson

There are no affiliations available

Personalised recommendations